Financial Interest Disclosure (over the past 24 months) Before we begin. Background What is ILD? 8/18/2016
|
|
- Laura Goodman
- 6 years ago
- Views:
Transcription
1 Financial Interest Disclosure (over the past 24 months) SCLERODERMA LUNG DISEASE UPDATE Company Speaker Advisory Research Boehringer-Ingelheim September 2016 Hoffman La-Roche Intermune Shane Shapera, MD, FRCPC Interstitial Lung Disease Program Director Toronto General Hospital, University Health Network Assistant Professor, University of Toronto Medimmune Prometic Sanofi I have taken many images from the internet for this talk full links are provided At the end of this session, participants will be able to: Describe Scleroderma-related interstitial lung disease (SSc-ILD) Before we begin I will need to define some medical terms Understand the risk factors for SSc-ILD development and its progression Discuss current evidence of treatment of SSc-ILD Anticipate future treatments for SSc-ILD Appreciate the role of lung transplant in SSc-ILD Background What is ILD? (Interstitial Lung Disease) Background What is ILD? What is it? Chronic, progressive scarring of the scaffolding of the lung Cause may be known (Scleroderma, RA, exposures, etc ) Cause often unknown (idiopathic interstitial pneumonia - IPF) Why is it bad? Stiff lungs more work to breathe breathless Scarred lungs poor gas exchange low Oxygen levels Progressive lung function can get worse over time &cad=rja&uact=8&ved=0ahukewj4rsn0gzfoahuiwt4khqn9dtuqjr wibw&url=http%3a%2f%2fwww.fpnotebook.com%2flung%2fanato my%2flngantmy.htm&bvm=bv ,d.cww&psig=afqjcnf6y PEOCpwoIJb9miiGxRV-b_NPlQ&ust= ges&cd=&cad=rja&uact=8&ved=0ahukewja5uw3gzfoahum ET4KHQSBAroQjRwIBw&url=http%3A%2F%2Fdepts.washing ton.edu%2fenvh%2flung.html&psig=afqjcnh1xbj2fr_e6td pwfnb3rrnwjunfq&ust=
2 Scarring diseases (like ILD) cause the lungs to become stiff and shrink We measure this shrinkage of the lungs to diagnose and monitor ILD Total lung capacity (TLC) is a measure of all of the air in the lungs We measure TLC using a machine called a plathysmograph (Body Box) ahukewjukrdyg5foahvbmz4khthxbyaqjrwibw&url=http%3a%2f%2fmemim.com%2fbody -plethysmography.html&bvm=bv ,d.cww&psig=afqjcnfvivci_uha1dbwpdeth- FfZ2-GsA&ust= KHD4KHYU1AxwQjRwIBw&url=http%3A%2F%2Fwww.tiem.utk.edu%2F~gross%2Fbioed%2Fwebmodules%2Flungcapa city.html&bvm=bv ,d.cww&psig=afqjcnf2xcjnyvcy6gdujexnub3t0wdt6a&ust= In ILD, the lungs stiffen and shrink The Total Lung Capacity (TLC) gets smaller Other measures (like FVC) go down with TLC FVC is easier and cheaper to measure than TLC We use FVC to monitor for progression of ILD Who gets SSc-ILD? SSc-ILD occurs in up to half of patients with SSc Many patients have mild ILD without symptoms Some can have severe and/or progressive disease ILD is a major cause of disability and death in SSc Not everyone with SSc-ILD needs treatment We only treat patients who are getting worse over time How do we predict who will have mild disease and who will progress over time? Wells AU, et al, Semin Repir Crit Care Med 2014;35:
3 Risk Factors For Progressive ILD Ms. S.C. Recent diagnosis of SSc (within 4-5 years) High volume of abnormal lung (> 20%) Low lung function at baseline (FVC < 70%) Dropping lung function (FVC drops 10%) over 6-12 months 58 year old woman with Scleroderma Lives in Thunder Bay and flies to Toronto for visits Referred to my clinic in 2008 for lung assessment Fit and active with no lung symptoms Comes back 3 years later Breathless for about 6 months Dry hacking cough Slowly getting worse Not improving after antibiotics and puffers Wells AU, et al, Semin Repir Crit Care Med 2014;35: Treatment of SSc-ILD Date Dec Dec May FVC 2.3 L 2.0L 1.7 L Many treatments for SSc have no impact on ILD Some treatments for SSc may be harmful in ILD There are some drugs that we think may help improve lung function: Azathioprine Cyclophosphamide Mycophenolate Prednisone Rituximab 3
4 FVC FVC 8/18/2016 SSc-ILD Treatment: SLS-1 Scleroderma Lung Study 1 acebo x 1 year Oral Cyclophosphamide vs. Placebo for 1 year Modest improvement in FVC at 1 year Further FVC increase at 18 months Benefits lost after 1 year without treatment Side effects common (low blood counts, bladder problems & risk of cancer) FVC<70% benefit most FVC 6.8% at 18 months versus placebo (p = 0.006) End of treatment Time 18 months 2 years SLS-1: Take Home Messages Cyclophosphamide was the first drug to show that we can improve lung function in patients with SSc-ILD Some benefits continue for months even after drug is stopped Lung improvement peaks 6 months after finishing treatment Patients with more severe disease and those most likely to progress seem to get the most benefit Side effects are common and can be serious Are there other less toxic treatments that work? Tashkin DP et al, N Engl J Med 2006;354: Tashki DP et al. Am J Respir Crit Care Med 2007;176: SSc-ILD Treatment: SLS-2 Scleroderma Lung Study 2 SLS-2: Take home messages Year 1 Year 2 Cyclophosphamide and Mycophenolate both improve lung function 142 patients Time A B Oral Cyclophosphamide 2mg/kg/day Mycophenolate 1.5g twice daily FVC improved similarly in both groups More side effects with Cyclophosphamide No treatment Mycophenolate 1.5g twice daily Low blood counts (RBC, WBC, platelets) More Cyclophosphamide patients had to stop drug for side effects (36 vs. 20 patients, p = 0.019) Tashkin DP, et al. Lancet Respir Med Jul 25. pii: S (16) [epub ahead of print] Cyclophosophamide has more side effects than Mycophenolate There are still a lot of unanswered questions Are there some patients that benefit more than others? When is the right time to start these drugs? Is there a role for Cyclophosphamide first followed by Mycophenolate maintenance therapy? Should Cyclophosphamide be used as salvage treatment for patients who are getting worse on Mycophenolate? Many doctors are using both drugs in sequence Cyclophosphamide followed by Mycophenolate Mycophenolate followed by Cyclophosphamide Studies looking at using both drugs will probably never happen Ms. S. C. Date Ms. S. C. had a detailed discussion with her doctor She decided to take 6 months of Cyclophosphamide Followed by long term Mycophenolate for over 2 years This is an example of using both drugs in sequence Dec 2008 Dec 2010 May 2011 Nov 2011 Feb 2012 June 2012 Jan 2013 May 2014 Dec 2014 FVC 2.3 L 2.0L 1.7 L 1.9 L 2.1 L 2.2 L 2.2 L 2.2 L 2.4 L The Future? Rituximab in SSc-ILD Rituximab is a biologic treatment use to treat Rheumatoid Arthritis Given as 2 injections 2 weeks apart every 6 months Makes the body stop making anti-bodies (B-cells) Increases risk of infection Very few other side effects Currently being studied in SSc-ILD (RECITAL trial) Comparing Rituximab vs. Cyclophosphamide Results expected in 2018 Cyclophosphamide Mycophenolate 4
5 Survival (%) Number of LTx '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 8/18/2016 History of the Toronto Lung Transplant Program 1 st Single lung Dr. Joel Cooper in st Double lung Dr. Joel Cooper in 1986 Lung transport solution Dr. Shaf Keshavjee in 1989 Ex-Vivo lung perfusion Dr Shaf Keshavjee 2008 History of the Toronto Lung Transplant Program 1 st Single lung Dr. Joel Cooper in st Double lung Dr. Joel Cooper in 1986 Lung transport solution Dr. Shaf Keshavjee in 1989 Ex-Vivo lung perfusion Dr Shaf Keshavjee 2008 History of the Toronto Lung Transplant Program 1 st Single lung Dr. Joel Cooper in 1983 Lung transplants in Toronto per year ( ) 150 LTx/Year st Double lung Dr. Joel Cooper in Lung transport solution Dr. Shaf Keshavjee in Ex-Vivo lung perfusion Dr Shaf Keshavjee Year LTx/Year Slide courtesy of Sassan Azad Lung Transplantation Survival (TLTP vs. ISHLT) January 1990 June 2012 Lung transplantation: Who is a candidate? ISHLT (N=43,501) TLTP (N=1,180) Median survival (years): ISHLT = 5.6 vs. TLTP ~ 7.0 Severe and progressive ILD that is not responding to medical therapy Patients who are otherwise quite healthy 25 Willing to relocate close to a transplant center Years Slide courtesy of Sassan Azad 5
6 Summary SSc-ILD occurs in half of patients with SSc Risk factors for progression: early and severe disease SSc-ILD is a major cause of disability and death Progression of SSc-ILD is monitored using FVC Cyclophosphamide has been shown to improve FVC Side effects are very common Mycophenolate has recently been shown to also improve FVC Less side effects than Cyclophosphamide More patients are able to stay on treatment New treatments (Rituximab) are currently being studied Lung transplant can be a last resort option for some patients 6
Emerging Therapies for Lung Fibrosis. Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow
Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the tissue that supports the lungs alveoli
More informationHypersensitivity Pneumonitis (HP)
Hypersensitivity Pneumonitis (HP) Information for patients and families UHN Read this handout to learn about: What hypersensitivity pneumonitis (HP) is Signs and symptoms How your doctor will know if you
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationTODAY IS THE DAY I STAND UP TO IPF. fightipf.co.uk
fightipf.co.uk SUPPORTING IPF AWARENESS TODAY IS THE DAY I STAND UP TO IPF For people diagnosed with Idiopathic Pulmonary Fibrosis: A guide to help you discuss your condition and management options with
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationLung Transplantation: Overview and the MUSC Program
Lung Transplantation: Overview and the MUSC Program Timothy P.M. Whelan MD Associate Professor of Medicine Medical Director of Lung Transplantation History of Lung Transplant James Hardy Univ of Mississippi
More informationMyositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationManagement of Idiopathic Pulmonary Fibrosis
Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1
More informationDRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)
Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) Reference: NHS England A/14/X01 CHECK Information Reader Box (IRB) to be
More informationNOT COPY. Choice of the primary outcome: Pro Lung 03/09/2018. Lung assessment in clinical trials
Choice of the primary outcome: Pro Lung Christopher P. Denton Professor of Experimental Rheumatology Royal Free Hospital and University College London, UK Florence 7 th September 218 Improved clinical
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationUpdate in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates
Update in Systemic Sclerosis! Lauren Kim MD! NW Rheumatology Associates Review Systemic sclerosis affects approximately 75,000 to 100,000 people in the U.S. and has the highest mortality rate of any autoimmune
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationChronic Obstructive Pulmonary Disease. Information about medication and an Action Plan to use if your condition gets worse due to an infection
Chronic Obstructive Pulmonary Disease Information about medication and an Action Plan to use if your condition gets worse due to an infection Information about your medication Your usual treatment Inhalers
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationMEDICATIONS: THE GOOD, THE BAD, THE UGLY
MEDICATIONS: THE GOOD, THE BAD, THE UGLY July 13, 2013 Dr. Tanaz Kermani Assistant Clinical Professor of Medicine, Division of Rheumatology, David Geffen School of Medicine UCLA Dr. Robert Spiera Professor
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationMarcelo Cypel MD MSc
Ex vivo Organ Repair Marcelo Cypel MD MSc Canada Research Chair in Lung Transplantation Surgical Director ECLS Program UHN Assistant Professor of Surgery Division of Thoracic Surgery University Health
More informationTracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust
Interstitial Lung Disease (ILD) Tracy Ward Highly Specialist Respiratory Nurse Rotherham NHS Foundation Trust The views expressed in this presentation are those of the speaker and are not necessarily those
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationWHEN COPD* SYMPTOMS GET WORSE
WHEN COPD* SYMPTOMS GET WORSE Boehringer Ingelheim Pharmaceuticals, Inc. has no ownership interest in any other organization that advertises or markets its disease management products and services. *Includes
More informationDisclosures. Integrated Approach to Treating CTD-ILD. Limitations. Relevant items to consider. Other than for SSc-ILD, no controlled data
Integrated Approach to Treating CTD-ILD Industry relationships: Disclosures Aryeh Fischer, MD Associate Professor of Medicine Division of Rheumatology Division of Pulmonary Sciences and Critical Care Medicine
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationPNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera
PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e
More informationAsthma. & Older Adults. A guide to living with asthma for people aged 65 years and over FOR PATIENTS & CARERS
Asthma & Older Adults A guide to living with asthma for people aged 65 years and over FOR PATIENTS & CARERS what is Asthma? Asthma is a disease of the airways, the small tubes which carry air in and out
More informationConflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck
Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationEmphysema. Lungs The lungs help us breathe in oxygen and breathe out carbon dioxide. Everyone is born with 2 lungs: a right lung and a left lung.
Emphysema Introduction Emphysema is a type of chronic obstructive pulmonary disease, or COPD. COPD affects millions of people worldwide. Emphysema involves damage to the air sacs in the lungs. This makes
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationCADTH CDEC FINAL RECOMMENDATION
CADTH CDEC FINAL RECOMMENDATION NINTEDANIB (Ofev Boehringer Ingelheim Canada Ltd.) Indication: Idiopathic Pulmonary Fibrosis Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends that
More informationDear Reader, What was the study about? Why was the research needed? BI NCT
Dear Reader, Sponsors of clinical studies create study reports. A study report describes how the study was done and what the results of the study were. This is a summary of such a report. It is meant for
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and
More informationTODAY IS THE DAY I STAND UP TO IPF. fightipf.ca. Talking to your doctor about IPF and your options
fightipf.ca SUPPORTING PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS TODAY IS THE DAY I STAND UP TO IPF Talking to your doctor about IPF and your options WHAT IT MEANS TO HAVE IPF Idiopathic Pulmonary Fibrosis,
More informationPerspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
More informationCOPD Research at the University of Maryland School of Maryland
COPD Research at the University of Maryland School of Maryland COPD Clinical Research Center A member of the National Heart Lung & Blood Institute National Institutes of Health Director: Steven M. Scharf,
More informationChronic Obstructive Pulmonary Disease A breathtaking condition
1. Jan Crouch JC 2. Diane Cruikshank DC 3. Jillian Millar Drysdale JMD 4. Medical Editor 5. Robert Clarke Article: COPD & smoking.doc Section: Growing Older Family Health: Fall 2008 Chronic Obstructive
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More information4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed
Demystifying weakness: how to approach refractory myositis Jemima Albayda, MD Assistant Professor Johns Hopkins Myositis center Disclosures Off-label uses for medications will be discussed Objectives To
More informationBronchiectasis. What is bronchiectasis? What causes bronchiectasis?
This factsheet explains what bronchiectasis is, what causes it, and how it is diagnosed and managed. More detailed information is available on the Bronchiectasis Patient Priorities website: www.europeanlunginfo.org/bronchiectasis
More informationTake on IPF progression with OFEV
Every breath matters Take on IPF progression with OFEV Learn more at www.ofev.com IPF=idiopathic pulmonary fibrosis. Please see throughout Understand how IPF affects you Idiopathic pulmonary fibrosis (IPF)
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationwritten by Harvard Medical School COPD It Can Take Your Breath Away
written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are 2 major diseases included in COPD:
More informationDOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017
DOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017 Disclosures for David Garcia Consultancy: Boehringer Ingelheim; Bristol-Meyers Squibb; Daiichi
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationGet Healthy Stay Healthy
Asthma Management WHAT IS ASTHMA? Asthma causes swelling and inflammation in the breathing passages that lead to your lungs. When asthma flares up, the airways tighten and become narrower. This keeps the
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationThe Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
More informationGLPG1690 FLORA topline results
GLPG1690 FLORA topline results Webcast presentation 10 August 2017 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the potential activity
More informationdifferent phenotypes
Pulmonary hypertension in scleroderma: different phenotypes UMR 995 Pr David LAUNAY, MD, PhD launayd@gmail.com Service de Médecine Interne. Unité d'immunologie Clinique CNRMR Maladies Systémiques et Autoimmunes
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationDoctor office visit checklist
Doctor office visit checklist Before the visit Gather your questions Identify symptoms Check your loved one s file Call to confirm appointment Take a list of any medicines the patient is currently taking
More informationFurther information You can get more information and share your experience at
OS02 Total Knee Replacement Further information You can get more information and share your experience at www.aboutmyhealth.org Local information You can get information locally from: Taunton and Somerset
More informationPatient Information for Consent
Patient Information for Consent OS01 Total Hip Replacement Expires end of February 2017 Issued June 2016 Local information If you need any more information please contact your BMI hospital on:...... Get
More informationChronic Obstructive Pulmonary Disease (COPD)
James Paget University Hospitals NHS Foundation Trust Great Yarmouth and Waveney Clinical Commissioning Group HealthEast Chronic Obstructive Pulmonary Disease (COPD) Information and Advice for Patients
More informationPatient information from BMJ
Patient information from BMJ Last published: Dec 02, 2016 Lung cancer (non-small-cell) It can be devastating to find out that you or someone close to you has lung cancer. You will have to make some important
More informationInflammatory arthritis Shared Decision Making
Inflammatory arthritis Shared Decision Making DMARDs El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com Copyrights reserved Contents 1 2 3
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationLung health and you. Looking after your lungs and steps to stay well.
Lung health and you Looking after your lungs and steps to stay well www.roycastle.org Staying well Your lungs supply oxygenated blood to your heart and other vital organs. Your lungs can be damaged by
More informationUNDERSTANDING & MANAGING
UNDERSTANDING & MANAGING YOUR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)* *Includes chronic bronchitis, emphysema, or both Boehringer Ingelheim Pharmaceuticals, Inc. has no ownership interest in any
More informationLymphangioleiomyomatosis (LAM)
Lymphangioleiomyomatosis (LAM) is a rare lung condition that mainly affects women of childbearing age. Although it has been reported in men, it is extremely rare. It is estimated that three to five in
More informationEasyRead guide to the PowerPoint slides. This is an EasyRead guide to the slides you will see on the screen.
EasyRead guide to the PowerPoint slides This is an EasyRead guide to the slides you will see on the screen. It has the slide you will see on the screen at the top of the page and an EasyRead of what it
More informationA patient educational resource provided by Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. has no ownership interest in any other organization that advertises or markets its disease management products and services. A patient educational resource provided
More informationPatient Information for Consent
Patient Information for Consent ER OS01 Total Hip Replacement Enhanced Recovery Expires end of February 2017 Issued June 2016 Local information If you need any more information please contact your BMI
More informationEvidence Review: Title. Month/ Year. Evidence Review:
Evidence Review: Title Month/ Year Evidence Review: Rituximab for connective tissue disease associated interstitial lung disease October 2014 Standard Operating Procedure: NHS England Evidence Review:
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationDéjà vu all over again
Disclosures Déjà vu all over again None Jonathan Singer MD MS University of California, San Francisco HPI 49 y/o woman presents for lung transplant evaluation for Hypersensitivity Pneumonitis Exposures:
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationDEPARTMENT OF RHEUMATOLOGY
DEPARTMENT OF RHEUMATOLOGY PG Teaching Schedule Theory (8 30 am to 9am) DATE TOPIC PRESENTER FACULTY 01/10/16 Approach to Arthritis Dr. Sandeep Dr. Suma Balan 03/10/16 Cardiovascular risk in Rheumatic
More informationOptimizing the Lung Transplant Candidate through Exercise Training. Lisa Wickerson BScPT, MSc Canadian Respiratory Conference April 25, 2014
Optimizing the Lung Transplant Candidate through Exercise Training Lisa Wickerson BScPT, MSc Canadian Respiratory Conference April 25, 2014 Conflicts of Interest None to declare Learning Objectives At
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationDisclosures. Scleroderma: Early Diagnosis How early is early? 10/28/2013. Difficult Scleroderma: How do I Approach this Patient?
Disclosures Financial support: None Difficult Scleroderma: How do I Approach this Patient? Francesco Boin, MD Assistant Professor of Medicine Director, Translational Research Johns Hopkins Scleroderma
More informationStiff Shoulder Tips for decreasing your pain and increasing movement
Patient Education Tips for decreasing your pain and increasing movement Your stiff shoulder may be painful and limit your movement. There are many causes of shoulder stiffness. Most times stretching exercises
More informationTotal ankle replacement. Brought to you in association with EIDO Healthcare and endorsed by the Royal College of Surgeons England.
Total ankle replacement Brought to you in association with EIDO Healthcare and endorsed by the Royal College of Surgeons England. Discovery has made every effort to ensure that we obtained the information
More informationRegulatory Status FDA-approved indication: Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF) (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.05 Subject: Ofev Page: 1 of 5 Last Review Date: March 17, 2017 Ofev Description Ofev (nintedanib)
More informationDisclosures. Learning Objectives. Improving HPV Immunization Rates in a Large Pediatric Practice: Implementing Effective Quality Improvement
Improving HPV Immunization Rates in a Large Pediatric Practice: Implementing Effective Quality Improvement Alix Casler, M.D., F.A.A.P. Medical Director of Pediatrics, Orlando Health Physician Associates
More informationMoving forward. with idiopathic pulmonary fibrosis (IPF) A guide to your journey ahead
Moving forward with idiopathic pulmonary fibrosis (IPF) A guide to your journey ahead 3 Table of contents Now that you know more about your disease, you can begin to learn how to live the best life you
More informationPa#ent Informa#on for Consent
Pa#ent Informa#on for Consent ER_OS02 Total Knee Replacement Enhanced Recovery Expires end of November 2018 Local Informa#on For further informa0on locally you can contact the Pa0ent Advice & Liaison Service
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationBronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh
Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.
More informationSupported by an educational grant from
IDIOPATHIC PULMONARY FIBROSIS: PATIENT INFORMATION BROCHURE Supported by an educational grant from 08232-106 CONTENTS What is Pulmonary Fibrosis?.......................................................
More informationAcute and chronic treatments
21st Annual Meeting of the Swiss Stroke Society Lausanne, 11 January 2018 Vasculitis and stroke : Acute and chronic treatments Pr Mathieu ZUBER Service de Neurologie et NeuroVasculaire Groupe Hospitalier
More informationRadiotherapy to one side of the mouth and neck
Clinical Oncology Radiotherapy to one side of the mouth and neck Consent information for patients Radiotherapy may be given on its own or with chemotherapy (separate information will be given about chemotherapy).
More informationLUNG CANCER CLINICAL TRIALS
UNDERSTANDING SERIES LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT THE BASICS ABOUT CLINICAL TRIALS WITH MORE INFORMATION YOU CAN MAKE BETTER CHOICES. The decision
More informationNATIONAL ASSOCIATION FOR CONTINUING EDUCATION
Outcome Report Update on Idiopathic Pulmonary Fibrosis: State of the Art and the New Guidelines NATIONAL ASSOCIATION FOR CONTINUING EDUCATION Presented at: Cleveland Clinic Florida Weston, Florida December
More informationDiagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016
Diagnosis and Management of Immune Thrombocytopenias Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016 Disclosures Research support: NIH, CDC, Eisai, Pfizer, Daiichi Sankyo, GlaxoSmithKline,
More informationRadiotherapy to your breast or chest wall
Radiotherapy to your breast or chest wall The name of your consultant is: The radiographer who explained the treatment to you is: You can contact us on: What is radiotherapy? Radiotherapy treats cancer
More information